INR 492.5
(6.9%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 940.36 Million INR | 10.5% |
2022 | 851.03 Million INR | 7.42% |
2021 | 792.23 Million INR | 30.23% |
2020 | 608.34 Million INR | 1.28% |
2019 | 600.66 Million INR | 20.23% |
2018 | 499.58 Million INR | 16.34% |
2017 | 429.42 Million INR | -7.89% |
2016 | 466.19 Million INR | 10.71% |
2015 | 421.09 Million INR | -18.2% |
2014 | 514.78 Million INR | 7.15% |
2013 | 480.4 Million INR | -2.98% |
2012 | 495.16 Million INR | 1.46% |
2011 | 488.05 Million INR | -1.61% |
2010 | 496.05 Million INR | 19.76% |
2009 | 414.21 Million INR | 26.09% |
2008 | 328.5 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -2 Billion INR | -313.2% |
2023 Q4 | 940.36 Million INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 Q2 | 975.08 Million INR | 0.0% |
2023 FY | 940.36 Million INR | 10.5% |
2023 Q1 | - INR | -100.0% |
2022 Q2 | 728.54 Million INR | 0.0% |
2022 FY | 851.03 Million INR | 7.42% |
2022 Q3 | - INR | -100.0% |
2022 Q4 | 851.03 Million INR | 0.0% |
2022 Q1 | - INR | -100.0% |
2021 Q4 | 792.23 Million INR | 0.0% |
2021 Q3 | - INR | -100.0% |
2021 Q2 | 634.13 Million INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2021 FY | 792.23 Million INR | 30.23% |
2020 Q1 | - INR | -100.0% |
2020 FY | 608.34 Million INR | 1.28% |
2020 Q4 | 608.34 Million INR | 0.0% |
2020 Q3 | - INR | -100.0% |
2020 Q2 | 578.57 Million INR | 0.0% |
2019 Q4 | 600.66 Million INR | 0.0% |
2019 Q3 | - INR | -100.0% |
2019 FY | 600.66 Million INR | 20.23% |
2019 Q2 | 451.41 Million INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2018 Q3 | - INR | -100.0% |
2018 Q2 | 424.23 Million INR | 0.0% |
2018 Q1 | - INR | -100.0% |
2018 FY | 499.58 Million INR | 16.34% |
2018 Q4 | 499.58 Million INR | 0.0% |
2017 Q3 | - INR | -100.0% |
2017 Q1 | - INR | -100.0% |
2017 Q4 | 429.42 Million INR | 0.0% |
2017 FY | 429.42 Million INR | -7.89% |
2017 Q2 | 518.51 Million INR | 0.0% |
2016 Q2 | 427.43 Million INR | 0.0% |
2016 FY | 466.19 Million INR | 10.71% |
2016 Q1 | - INR | -100.0% |
2016 Q3 | - INR | -100.0% |
2016 Q4 | 466.19 Million INR | 0.0% |
2015 Q2 | 500.11 Million INR | 0.0% |
2015 Q4 | 421.09 Million INR | 0.0% |
2015 Q1 | - INR | -100.0% |
2015 Q3 | - INR | -100.0% |
2015 FY | 421.09 Million INR | -18.2% |
2014 Q3 | - INR | -100.0% |
2014 FY | 514.78 Million INR | 7.15% |
2014 Q4 | 514.78 Million INR | 0.0% |
2014 Q2 | 506.27 Million INR | 0.0% |
2014 Q1 | - INR | -100.0% |
2013 Q1 | - INR | -100.0% |
2013 Q3 | - INR | -100.0% |
2013 Q4 | 480.4 Million INR | 0.0% |
2013 FY | 480.4 Million INR | -2.98% |
2013 Q2 | 433.66 Million INR | 0.0% |
2012 Q2 | 466.09 Million INR | 0.0% |
2012 FY | 495.16 Million INR | 1.46% |
2012 Q4 | 495.16 Million INR | 0.0% |
2011 FY | 488.05 Million INR | -1.61% |
2011 Q4 | 488.05 Million INR | 0.0% |
2010 FY | 496.05 Million INR | 19.76% |
2009 FY | 414.21 Million INR | 26.09% |
2008 FY | 328.5 Million INR | 0.0% |
2008 Q4 | 328.5 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 94.222% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.382% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 81.849% |
Granules India Limited | 22.95 Billion INR | 95.903% |
Indoco Remedies Limited | 10.34 Billion INR | 90.908% |
Achyut Healthcare Limited | 2.01 Million INR | -46614.704% |
Ajanta Pharma Limited | 10.71 Billion INR | 91.22% |
Alkem Laboratories Limited | 48.6 Billion INR | 98.065% |
Alpa Laboratories Limited | 307.12 Million INR | -206.187% |
Brooks Laboratories Limited | 248.6 Million INR | -278.264% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 74.315% |
Bajaj HealthCare Limited | 4.86 Billion INR | 80.681% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 55.409% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.121% |
Eris Lifesciences Limited | 38.26 Billion INR | 97.543% |
FDC Limited | 3.7 Billion INR | 74.648% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 98.556% |
Gufic Biosciences Limited | 5.59 Billion INR | 83.207% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 58.926% |
Ipca Laboratories Limited | 33.74 Billion INR | 97.213% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -216.878% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 68.379% |
Lasa Supergenerics Limited | 541.92 Million INR | -73.523% |
Laurus Labs Limited | 42.71 Billion INR | 97.798% |
Lupin Limited | 96.23 Billion INR | 99.023% |
Mankind Pharma Limited | 23.87 Billion INR | 96.061% |
Medico Remedies Limited | 438.24 Million INR | -114.576% |
Megasoft Limited | 1.85 Billion INR | 49.256% |
NATCO Pharma Limited | 10.53 Billion INR | 91.071% |
Piramal Pharma Limited | 74 Billion INR | 98.729% |
RPG Life Sciences Limited | 1.38 Billion INR | 31.867% |
Sigachi Industries Limited | 2.53 Billion INR | 62.85% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.488% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 53.773% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 19.296% |
Unichem Laboratories Limited | 8.06 Billion INR | 88.346% |
Wanbury Limited | 3.15 Billion INR | 70.199% |
Windlas Biotech Limited | 1.76 Billion INR | 46.652% |
ZIM Laboratories Limited | 2.08 Billion INR | 54.807% |
Zydus Lifesciences Limited | 71.79 Billion INR | 98.69% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 75.844% |
Divi's Laboratories Limited | 18.99 Billion INR | 95.048% |
Hester Biosciences Limited | 3.59 Billion INR | 73.84% |
Procter & Gamble Health Limited | 2.56 Billion INR | 63.284% |
Amrutanjan Health Care Limited | 783.82 Million INR | -19.972% |
Bal Pharma Limited | 2.51 Billion INR | 62.554% |
Strides Pharma Science Limited | 37.68 Billion INR | 97.504% |
Venus Remedies Limited | 1.39 Billion INR | 32.484% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 88.603% |
Nectar Lifesciences Limited | 11.21 Billion INR | 91.617% |
Shilpa Medicare Limited | 12.93 Billion INR | 92.729% |
Aarti Drugs Limited | 11.5 Billion INR | 91.826% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 85.142% |
Suven Life Sciences Limited | 148.62 Million INR | -532.728% |
Ind-Swift Limited | 13.45 Billion INR | 93.01% |
Valiant Laboratories Limited | 1.05 Billion INR | 11.14% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 91.218% |
Solara Active Pharma Sciences Limited | 14.14 Billion INR | 93.351% |
Themis Medicare Limited | 1.88 Billion INR | 50.18% |
Hikal Limited | 12.99 Billion INR | 92.764% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 98.854% |
Sequent Scientific Limited | 8.27 Billion INR | 88.635% |
Novartis India Limited | 1.8 Billion INR | 47.789% |
Wockhardt Limited | 39.87 Billion INR | 97.641% |
Jubilant Pharmova Limited | 61.27 Billion INR | 98.465% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -225.613% |
Neuland Laboratories Limited | 5.49 Billion INR | 82.898% |
Morepen Laboratories Limited | 4.45 Billion INR | 78.915% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -46.046% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 52.418% |